The power of precision: Atomic Oncology's revolutionary cancer tech

Atomic Oncology is revolutionizing radiotherapy with its precision cancer tech. Learn more about the power of precision and how it can help in the fight against cancer.

13 July 2023

With its groundbreaking technology, Atomic Oncology aims to revolutionise cancer radiotherapy by providing essential insights into tumour sensitivity to radiation. In this article, we will explore the remarkable advancements made by the Atomic Oncology team, shedding light on its potential to transform cancer care and improve patient outcomes.

Atomic Oncology has developed a groundbreaking test that accurately predicts the sensitivity or resistance of any tumour to radiation therapy, irrespective of its cancer type. This test represents a significant breakthrough, as no other approved diagnostic tool currently offers this crucial information. Traditionally, radiotherapy decisions have relied on subjective assessments, making it more of an art than a data-driven practice. However, with Atomic Oncology's innovative technology, this outdated paradigm is on the verge of change.

The urgent need for progress in radiotherapy

Radiotherapy, a cornerstone in the battle against cancer, is a vital treatment modality for over half of all cancer patients across the globe. It is employed in the management of a wide array of malignancies, including but not limited to, brain, breast, cervical, colorectal, lung, and prostate cancers. Despite its widespread use, a significant challenge persists in the form of inadequate data on tumour sensitivity. This lack of precise information often culminates in suboptimal treatment decisions, potentially compromising patient outcomes.

Recognising this critical issue, Atomic Oncology has positioned itself at the forefront of a transformative movement. The company is dedicated to bridging the gap between subjective decision-making, which is often influenced by individual clinician experience and intuition, and evidence-based treatment protocols. By doing so, the Company aims to usher in a new era of personalised, data-driven cancer care, enhancing the effectiveness of radiotherapy and ultimately improving patient survival and quality of life.

The visionary behind Atomic Oncology

Dr. George Miklos, the visionary founder of Atomic Oncology, brings extensive experience and expertise to the forefront. With an academic background at the Australian National University and involvement in the Human Genome Project, Dr. Miklos has advised renowned biotech and pharmaceutical companies, including Novartis. His past successes in establishing and taking two Australian biotech businesses public highlight his remarkable track record in the industry. Moreover, Dr. Miklos holds multiple granted patents on epigenetic detection systems in microorganisms, human diseases, and clinical radiotherapy.

Empowering precise treatment

At the heart of Atomic Oncology's innovative approach is their pioneering technology, Radnos. This groundbreaking tool is set to redefine clinical decision-making for medical and radiation oncologists, bringing a new level of precision and personalisation to cancer treatment. Radnos is designed to be compatible with a broad spectrum of radiation treatment modalities, including beam radiation therapy, brachytherapy, Gamma Knife, and Proton Beam therapy. The true innovation of Radnos, however, lies in its ability to establish a novel link between a cancer's atomic properties and its susceptibility to radiation intervention.

Radnos leverages the power of laser ablation and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS), a state-of-the-art analytical technique, to rapidly generate atomic maps of tumours. These maps offer unprecedented insights into a tumour’s unique characteristics and, crucially, its potential responsiveness to radiation treatment. This level of detail goes beyond traditional imaging and biopsy results, delving into the very atomic structure of the cancer.

Armed with this invaluable information, clinicians will be empowered to make more precise, individualised treatment decisions. Instead of relying on a one-size-fits-all approach, they will be able to tailor the treatment plan to the unique atomic profile of each patient's tumour. This will enhance the effectiveness of the treatment while also minimising potential side effects, leading to improved patient outcomes and quality of life. In essence, Radnos will transform the landscape of cancer treatment, making personalised, precision radio-oncology a reality.

Atomic Oncology has strategically planned its clinical development to encompass three cancer types: glioblastoma, prostate cancer, and non-Hodgkin lymphoma. By targeting a range of radiotherapy sensitivities, the business aims to demonstrate the broad applicability and impact of its technology.

A paradigm shift in cancer radiotherapy

Atomic Oncology, through its groundbreaking technology and extensive atomic research, is redefining the landscape of cancer radiotherapy. The insights gleaned from their work have been lauded as "totally unexpected" and "fundamentally important" by Nobel laureate biochemist Edmond Fischer, underscoring the potential of their approach to revolutionise patient treatment.

The company's innovative strides are not just reshaping the field of cancer radiotherapy, but also reimagining the very approach to treatment decisions. By offering unparalleled insights into tumour sensitivity to radiation, Atomic Oncology equips clinicians with the tools to make more precise, individualised treatment choices. This fusion of visionary leadership and pioneering technology positions the Company to make a profound and enduring impact on cancer care, heralding a new era of precision radio-oncology and improved patient outcomes.

If you'd like more information on Atomic Oncology, please get in touch.

Subscribe to the Curated blog

Gain access to our bespoke company research, economic analysis and sector forecasts designed for professional and institutional investors. Unsubscribe at any time.

Not your email address?


Al Sila Tower, ADGM Square, Al Maryah Island, Abu Dhabi, UAE

Curated Capital Ltd is authorised and regulated by the Financial Services Regulatory Authority, ADGM.

© 2024 Curated Capital Ltd. All rights reserved.